Originally published as JCO Early Release 10.1200/JCO.2002.04.123 on July 9 2002

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Douillard, J.-Y. Articles by Benner, S. E. Search for Related Content PubMed PubMed Citation Articles by Douillard, J.-Y. Articles by Benner, S. E. Social Bookmarking                            What's this?

Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer

From the Centre René Gauducheau, Nantes, France; University of Texas, M.D. Anderson Cancer Center, Houston, TX; Nova Scotia Cancer Center, Halifax, Canada; California Healthcare, Greenbrae, CA; North Middlesex and Guy’s Hospital, London, United Kingdom; London Regional Cancer Center, London, Canada; University of Pittsburgh Cancer Center, Pittsburgh, PA; and Bristol-Myers Squibb Company, Wallingford, CT.

Address reprint requests to Prof Jean-Yves Douillard, Centre René Gauducheau, Site Hospitalier Nord, Bld J. Monod, 44805 Saint Herblain Cedex, France; email: jy-douillard{at}nantes.fnclcc.fr

PURPOSE: This phase III study was designed to demonstrate equivalence in survival of oral uracil/tegafur (UFT) and oral leucovorin (LV) to conventional intravenous (IV) fluorouracil (5-FU) and LV in previously untreated metastatic colorectal carcinoma. Safety was also compared.

PATIENTS AND METHODS: Eight hundred sixteen patients were randomized to receive either UFT (300 mg/m²/d) and LV (75 or 90 mg/d) for 28 days every 35 days or IV bolus 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) for 5 days every 28 days.

RESULTS: UFT/LV produced survival comparable to the IV 5-FU/LV regimen. Median survival was 12.4 months (95% confidence interval [CI], 11.2 to 13.6 months) with UFT/LV and 13.4 months (95% CI, 11.6 to 15.4 months) with 5-FU/LV (P = .630). The hazard ratio for survival was 0.964 (95.6% CI, 0.826 to 1.125), supporting equivalent survival. The overall response rate did not differ between treatment arms (UFT/LV, 11.7%; 5-FU/LV, 14.5%; P = .232). Median time to progression favored 5-FU/LV (UFT/LV, 3.5 months; 5-FU/LV, 3.8 months; P = .011), but tumor assessment schedules differed between arms. UFT/LV significantly improved safety compared with 5-FU/LV. Diarrhea, nausea and vomiting, and stomatitis and mucositis were significantly less frequent with UFT/LV, as was myelosuppression. Patients treated with UFT/LV had fewer episodes of febrile neutropenia (P < .001) and documented infections (P < .05). Increased bilirubin, without other liver function abnormalities, was observed more often with UFT/LV (P < .001). Concomitant medications were more frequent with 5-FU/LV, including use of antibiotics, growth factors, and antiemetics.

CONCLUSION: UFT/LV provided a safer, more convenient oral alternative to a standard bolus IV 5-FU/LV regimen for metastatic colorectal cancer while producing equivalent survival.

This article was published ahead of print at www.jco.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. A. Tang, G. R. Pond, and E. X. Chen Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials Ann. Onc., October 29, 2009; (2009) mdp478v1. [Abstract] [Full Text] [PDF]

				W. Koizumi, N. Boku, K. Yamaguchi, Y. Miyata, A. Sawaki, T. Kato, Y. Toh, I. Hyodo, T. Nishina, T. Furuhata, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer Ann. Onc., October 14, 2009; (2009) mdp371v1. [Abstract] [Full Text] [PDF]

				H. Ishida, Y. Miyake, M. Fukunaga, Y. Watanabe, T. Kato, H. Takemoto, and H. Furukawa A Feasibility Study of UFT/LV and Irinotecan (TEGAFIRI) in Advanced or Metastatic Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304 Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 601 - 605. [Abstract] [Full Text] [PDF]

				A. D. Ricart, J. D. Berlin, K. P. Papadopoulos, S. Syed, D. W. Drolet, C. Quaratino-Baker, J. Horan, J. Chick, W. Vermeulen, A. W. Tolcher, et al. Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7947 - 7955. [Abstract] [Full Text] [PDF]

				E. Casado, P. Pfeiffer, J. Feliu, M. Gonzalez-Baron, L. Vestermark, and H. A. Jensen UFT (tegafur-uracil) in rectal cancer Ann. Onc., August 1, 2008; 19(8): 1371 - 1378. [Abstract] [Full Text] [PDF]

				N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines? Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13. [Abstract] [Full Text] [PDF]

				H. S. Hochster, W. Luo, E. C. Popa, B. T. Lyman, M. Mulcahy, P. A. Beatty, and A. B. Benson Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (>= 75 years old) Patients With Colorectal Cancer: ECOG 1299 J. Clin. Oncol., December 1, 2007; 25(34): 5397 - 5402. [Abstract] [Full Text] [PDF]

				P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]

				N. Kokudo, K. Hasegawa, and M. Makuuchi Control Arm for Surgery Alone Is Needed but Difficult to Obtain in Randomized Trials for Adjuvant Chemotherapy After Liver Resection for Colorectal Metastases J. Clin. Oncol., April 1, 2007; 25(10): 1299 - 1300. [Full Text] [PDF]

				J. A. Kopec, G. Yothers, P. A. Ganz, S. R. Land, R. S. Cecchini, H. S. Wieand, B. C. Lembersky, and N. Wolmark Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06 J. Clin. Oncol., February 1, 2007; 25(4): 424 - 430. [Abstract] [Full Text] [PDF]

				N. Han and S. Galandiuk Induction Chemoradiation for Rectal Cancer Arch Surg, December 1, 2006; 141(12): 1246 - 1252. [Abstract] [Full Text] [PDF]

				B. C. Lembersky, H. S. Wieand, N. J. Petrelli, M. J. O'Connell, L. H. Colangelo, R. E. Smith, T. E. Seay, J. K. Giguere, M. E. Marshall, A. D. Jacobs, et al. Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06 J. Clin. Oncol., May 1, 2006; 24(13): 2059 - 2064. [Abstract] [Full Text] [PDF]

				G. Beutel, H. Glen, P. Schoffski, J. Chick, S. Gill, J. Cassidy, and C. Twelves Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors Clin. Cancer Res., August 1, 2005; 11(15): 5487 - 5495. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt and R. J. Mayer Systemic Therapy for Colorectal Cancer N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487. [Full Text] [PDF]

				C. J. A. Punt New options and old dilemmas in the treatment of patients with advanced colorectal cancer Ann. Onc., October 1, 2004; 15(10): 1453 - 1459. [Abstract] [Full Text] [PDF]

				K. Shirao, P.M. Hoff, A. Ohtsu, P.J. Loehrer, I. Hyodo, S. Wadler, R.G. Wadleigh, P.J. O'Dwyer, K. Muro, Y. Yamada, et al. Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/Tegafur (UFT) Plus Oral Leucovorin (LV) Regimen Between Japanese and American Patients With Advanced Colorectal Cancer: Joint United States and Japan Study of UFT/LV J. Clin. Oncol., September 1, 2004; 22(17): 3466 - 3474. [Abstract] [Full Text] [PDF]

				C. Fernandez-Martos, J. Aparicio, C. Bosch, M. Torregrosa, J. M. Campos, S. Garcera, J. M. Vicent, I. Maestu, M. A. Climent, J. L. Mengual, et al. Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years' Follow-Up J. Clin. Oncol., August 1, 2004; 22(15): 3016 - 3022. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				E. Diaz-Rubio New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers Oncologist, June 1, 2004; 9(3): 282 - 294. [Abstract] [Full Text] [PDF]

				R. B. Diasio Adjuvant Chemotherapy for Adenocarcinoma of the Lung -- Is the Standard of Care Ready for Change? N. Engl. J. Med., April 22, 2004; 350(17): 1777 - 1779. [Full Text] [PDF]

				A. Grothey, D. Sargent, R. M. Goldberg, and H.-J. Schmoll Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment J. Clin. Oncol., April 1, 2004; 22(7): 1209 - 1214. [Abstract] [Full Text] [PDF]

				J.-S. Chen, T.-S. Yang, Y.-C. Lin, and Y.-Y. Jan A Phase II Trial of Tegafur-Uracil Plus Leucovorin (LV) in the Treatment of Advanced Biliary Tract Carcinomas Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 353 - 356. [Abstract] [Full Text] [PDF]

				I. Chau and D. Cunningham Chemotherapy in colorectal cancer: new options and new challenges Br. Med. Bull., December 1, 2002; 64(1): 159 - 180. [Abstract] [Full Text] [PDF]

				M. Friedman Of What Value Is Uracil/Tegafur Plus Leucovorin to Colorectal Cancer Patients? J. Clin. Oncol., September 1, 2002; 20(17): 3574 - 3575. [Full Text] [PDF]

				J. Carmichael, T. Popiela, D. Radstone, S. Falk, M. Borner, A. Oza, T. Skovsgaard, S. Munier, and C. Martin Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3617 - 3627. [Abstract] [Full Text] [PDF]